What are the causes, evaluation, and management of a hyperdynamic systolic function (ejection fraction >70%)?

Hyperdynamic Systolic Function (EF >70%)

A hyperdynamic left ventricular ejection fraction (EF >70%) is not a benign finding and is independently associated with increased mortality, particularly in critically ill patients with sepsis, and reflects underlying diastolic dysfunction and pathologic cardiovascular states rather than superior cardiac function.

Key Clinical Context

Hyperdynamic left ventricular ejection fraction (HDLVEF) represents a pathologic state, not enhanced cardiac performance. Multiple studies demonstrate that patients with HDLVEF have significantly worse outcomes compared to those with normal EF (55-70%) 1, 2, 3.

Causes and Underlying Mechanisms

Primary Etiologies:

In Critically Ill/Septic Patients:

• Severe vasoplegia and reduced systemic vascular resistance - the most important mechanism in sepsis 4, 2
• Compensatory hyperdynamic state from distributive shock
• Associated with higher vasopressor requirements 4
• Independent risk factors include: chronic liver disease, cancer, tachycardia, high vasopressor doses, and mechanical ventilation 4

In General Medical Populations:

• Diastolic dysfunction and heart failure with preserved EF (HFpEF) - present in 78% of patients with HDLVEF 1
• Hypertension (most common association)
• Female sex, advanced age, obesity, diabetes 1
• Small ventricular cavity size with increased relative wall thickness 1
• Ischemic heart disease (paradoxically associated with depressed EF, not HDLVEF) 2

Evaluation Approach

Echocardiographic Assessment:

Systolic Parameters:

• Document precise LVEF measurement
• Measure stroke volume and cardiac index (typically elevated in HDLVEF) 4
• Assess LV cavity size (typically small) 1
• Calculate relative wall thickness 1

Diastolic Function Evaluation (Critical):

• Mitral inflow E/A ratio (often elevated) 4
• Tissue Doppler e' velocity (reduced, indicating impaired relaxation) 1
• E/e' ratio (elevated, indicating increased filling pressures) 1
• Left atrial volume (typically enlarged) 1
• Tricuspid regurgitation peak gradient (elevated) 1
• Deceleration time (prolonged) 1

Hemodynamic Parameters:

• Systemic vascular resistance (markedly reduced in sepsis-related HDLVEF) 4, 2
• Central venous pressure 4

Clinical Assessment:

Look specifically for:

• Signs and symptoms of heart failure (present in 20% of HDLVEF patients) 1
• Evidence of sepsis/distributive shock (SOFA score, lactate, vasopressor requirements) 5, 4
• Underlying conditions: hypertension, diabetes, obesity, chronic liver disease, malignancy 1, 4
• Volume status and fluid balance 4

Laboratory Evaluation:

• Natriuretic peptides (BNP/NT-proBNP) - per 2022 AHA/ACC/HFSA guidelines, NT-proBNP >125 pg/mL or BNP >35 pg/mL supports HF diagnosis 6
• Serum lactate (elevated in septic patients with HDLVEF) 5, 4
• Assess for cardiac amyloidosis if clinically indicated (screening for monoclonal light chains, bone scintigraphy, genetic sequencing per 2022 guidelines) 7

Prognostic Implications

HDLVEF carries significantly worse prognosis:

• 90-day mortality: 58.9% in septic ICU patients with HDLVEF vs. 24.7% with normal EF 2
• 28-day mortality increased with adjusted OR 1.38 (95% CI 1.039-1.842) 3
• Long-term survival reduced with HR 1.56 (95% CI 1.38-1.76) in general medical populations 1
• Mortality correlates with vasopressor dose and inversely with systemic vascular resistance 4

Management Strategy

In Septic/Critically Ill Patients:

Primary Focus - Address Underlying Vasoplegia:

• Aggressive fluid resuscitation guided by hemodynamic parameters
• Vasopressor support targeting adequate systemic vascular resistance
• Source control for sepsis
• Avoid inotropic agents - the heart is already hyperdynamic; inotropes may worsen outcomes
• Monitor for development of septic cardiomyopathy

In Patients with Diastolic Dysfunction/HFpEF:

Per 2022 AHA/ACC/HFSA Guidelines 7, 6:

Class 2a Recommendations:

• SGLT2 inhibitors (strongest recommendation for HFpEF)
• Treat hypertension aggressively (Class 1 recommendation)
• Manage atrial fibrillation if present (Class 2a)

Class 2b Recommendations:

• Mineralocorticoid receptor antagonists (MRAs)
• Angiotensin receptor-neprilysin inhibitors (ARNi)
• ARBs

Avoid:

• Routine nitrates or phosphodiesterase-5 inhibitors (Class 3: No Benefit) 7

General Measures:

• Diuretics for volume overload symptoms
• Rate control if tachycardic (HR is independently associated with HDLVEF) 4
• Address comorbidities: diabetes, obesity, hypertension
• Consider referral to HF specialist for advanced HF evaluation if symptoms progress 7

Critical Pitfalls to Avoid

1. Do not assume HDLVEF represents "good" cardiac function - it is a marker of pathology and poor prognosis
2. Do not use inotropic agents in septic patients with HDLVEF - they are already hyperdynamic
3. Do not overlook diastolic dysfunction - comprehensive diastolic assessment is mandatory
4. Do not miss HFpEF diagnosis - 20% of HDLVEF patients have clinical heart failure 1
5. In sepsis, recognize HDLVEF as a marker of severe vasoplegia requiring aggressive vasopressor support, not cardiac dysfunction requiring inotropes

Special Populations

Patients with improved LVEF: If a patient previously had HFrEF and now has LVEF >40% (including hyperdynamic range), continue HFrEF guideline-directed medical therapy per 2022 guidelines 7.